BioLife Solutions Completes Repligen Merger and Nasdaq Delisting
TipRanks (Tue, 6-Oct 9:30 AM ET)
Repligen Completes Acquisition of BioLife Solutions
Globe Newswire (Tue, 6-Oct 9:05 AM ET)
Freshworks Set to Join S&P SmallCap 600
PRNewswire (Mon, 5-Oct 6:30 PM ET)
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?
PRNewswire (Fri, 11-Sep 1:06 PM ET)
Business Wire (Thu, 10-Sep 4:12 PM ET)
Business Wire (Sat, 29-Aug 5:31 AM ET)
BioLife Solutions Reports Second Quarter 2026 Financial Results
PRNewswire (Thu, 6-Aug 4:03 PM ET)
Globe Newswire (Thu, 30-Jul 12:08 PM ET)
Globe Newswire (Wed, 29-Jul 10:30 PM ET)
PRNewswire (Wed, 29-Jul 1:42 PM ET)
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Biolife Solutions trades on the NASDAQ stock market under the symbol BLFS.
As of October 8, 2026, BLFS stock price was flat at $38.61 with million shares trading.
BLFS has a beta of 0.84, meaning it tends to be less sensitive to market movements. BLFS has a correlation of 0.06 to the broad based SPY ETF.
BLFS has a market cap of $1.89 billion. This is considered a Small Cap stock.
Last quarter Biolife Solutions reported $28 million in Revenue and $.08 earnings per share. This beat revenue expectation by $898,576 and exceeded earnings estimates by $.04.
In the last 3 years, BLFS traded as high as $39.76 and as low as $8.92.
The top ETF exchange traded funds that BLFS belongs to (by Net Assets): VTI, VXF, DFAS, VTWO, DFAC.
BLFS has outperformed the market in the last year with a return of +41.2%, while the SPY ETF gained +16.1%. In the last 3 month period, BLFS beat the market returning +42.0%, while SPY returned +4.1%. However, in the most recent 2 weeks BLFS has underperformed the stock market by returning +0.1%, while SPY returned +0.9%.
BLFS support price is $37.83 and resistance is $39.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLFS shares will trade within this expected range on the day.